What's Next for Biotech and Health-Care Start-ups - Healthy Returns

Once-promising venture-backed start-ups are folding, while some companies with possible treatments have enjoyed a moment in the sun. But where will values be once the crisis is over? Which companies are set to gain — or lose — the most? Section 32's Mike Pellini and Biomatics Capital's Julie Sunderland speak to Chrissy Farr at Healthy Returns.